Recombinant Bordetella pertussis prn Protein ，His & SUMO

PRN recombinant proteins, derived from the "PRN" (Pertactin) gene of Bordetella pertussis, have gained attention in immunological and vaccine research due to their potential applications in the development of effective vaccines against respiratory infections. Pertactin is an important adhesin that plays a crucial role in the pathogenicity of B. pertussis, the bacterium responsible for whooping cough. As the incidence of this disease has resurged in many regions, there is an urgent need for improved vaccination strategies that can provide better and longer-lasting immunity. Researchers have focused on the production and characterization of PRN recombinant proteins to explore their immunogenic properties. These proteins can be utilized as vaccine candidates, either alone or in combination with other antigens, to enhance the immune response against B. pertussis. Furthermore, studying the structure-function relationship of PRN recombinant proteins may offer insights into designing more effective vaccines and therapeutics. The use of recombinant DNA technology allows for the efficient production of these proteins in various expression systems, facilitating large-scale production and extensive preclinical studies. Overall, the research on PRN recombinant proteins represents a promising avenue for advancing our understanding of Bordetella pertussis infection and improving public health outcomes through enhanced vaccine development.